Amalgamated Bank Mei Pharma, Inc. Transaction History

Amalgamated Bank

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.42 - $0.65 $7,436 - $11,509	-17,707 Closed	0 $0
Q1 2022 Jun 30, 2022	SELL	$0.54 - $2.74 $773 - $3,923	-1,432 Reduced 7.48%	17,707 $11,000
Q4 2021 Feb 15, 2022	SELL	$2.33 - $3.37 $1,227 - $1,775	-527 Reduced 2.68%	19,139 $51,000
Q3 2021 Oct 29, 2021	SELL	$2.52 - $2.99 $2,031 - $2,409	-806 Reduced 3.94%	19,666 $54,000
Q2 2021 Aug 16, 2021	BUY	$2.6 - $3.65 $12,243 - $17,187	4,709 Added 29.87%	20,472 $58,000
Q4 2020 Feb 12, 2021	BUY	$2.6 - $3.32 $2,366 - $3,021	910 Added 6.13%	15,763 $41,000
Q3 2020 Oct 30, 2020	SELL	$2.46 - $4.27 $937 - $1,626	-381 Reduced 2.5%	14,853 $46,000
Q2 2020 Aug 10, 2020	BUY	$1.45 - $4.3 $3,823 - $11,339	2,637 Added 20.93%	15,234 $63,000
Q1 2020 May 13, 2020	BUY	$0.75 - $2.55 $227 - $772	303 Added 2.46%	12,597 $20,000
Q3 2019 Nov 13, 2019	SELL	$1.48 - $2.52 $121 - $206	-82 Reduced 0.66%	12,294 $21,000
Q2 2019 Aug 14, 2019	BUY	$2.45 - $3.32 $30,321 - $41,088	12,376 New	12,376 $31,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $385M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

Stay updated on Amalgamated Bank with notifications on news.